These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 19419473)

  • 1. Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulin therapy.
    Asarch A; Razzaque Ahmed A
    Pediatr Dermatol; 2009; 26(2):197-202. PubMed ID: 19419473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
    Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
    N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
    Engineer L; Bhol KC; Ahmed AR
    J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Successful treatment of corticoid-resistant pemphigus with high-dose intravenous immunoglobulins].
    Sibaud V; Beylot-Barry M; Doutre MS; Beylot C
    Ann Dermatol Venereol; 2000 Apr; 127(4):408-10. PubMed ID: 10844264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
    Ahmed AR
    J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
    Sami N; Qureshi A; Ahmed AR
    Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oropharyngeal pemphigus vulgaris and clinical remission: a long-term, longitudinal study.
    Mignogna MD; Fortuna G; Leuci S; Ruoppo E
    Am J Clin Dermatol; 2010; 11(2):137-45. PubMed ID: 20141235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
    Gürcan HM; Ahmed AR
    Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulins].
    Szép Z; Danilla T; Buchvald D
    Cas Lek Cesk; 2005; 144(10):700-3. PubMed ID: 16279438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.
    Sami N; Letko E; Androudi S; Daoud Y; Foster CS; Ahmed AR
    Ophthalmology; 2004 Jul; 111(7):1380-2. PubMed ID: 15234140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris.
    Ahmed AR; Gürcan HM
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1073-9. PubMed ID: 21143649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-year clinico-therapeutic experience in pemphigus: a retrospective study of 54 cases.
    Mahajan VK; Sharma NL; Sharma RC; Garg G
    Int J Dermatol; 2005 Oct; 44(10):821-7. PubMed ID: 16207182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of IVIg treatment in severe pemphigus vulgaris.
    Baum S; Scope A; Barzilai A; Azizi E; Trau H
    J Eur Acad Dermatol Venereol; 2006 May; 20(5):548-52. PubMed ID: 16684282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
    Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D
    Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non-responsive to conventional therapy: clinical outcome and post-treatment long-term follow-up.
    Ahmed AR; Gürcan HM
    J Eur Acad Dermatol Venereol; 2012 Sep; 26(9):1074-83. PubMed ID: 21819451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy.
    Keskin DB; Stern JN; Fridkis-Hareli M; Razzaque Ahmed A
    Cytokine; 2008 Mar; 41(3):315-21. PubMed ID: 18289869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide.
    Pandya AG; Sontheimer RD
    Arch Dermatol; 1992 Dec; 128(12):1626-30. PubMed ID: 1456758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature.
    Fuertes I; Guilabert A; Mascaró JM; Iranzo P
    Dermatology; 2010 Aug; 221(1):13-6. PubMed ID: 20389028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
    Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
    Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris.
    Green MG; Bystryn JC
    Arch Dermatol; 2008 Dec; 144(12):1621-4. PubMed ID: 19075146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.